BLOOMFIELD, N.J.

新泽西州布卢姆菲尔德

,

，

June 3, 2026

2026年6月3日

/PRNewswire/ - SGS, the world's leading testing, inspection and certification company, is pleased to announce that it has acquired CMIC, INC., a specialized provider of bioanalytical testing services based in Chicago, Illinois (United States). Established in 2010, CMIC, INC. supports North American pharmaceutical and biotech manufacturers with bringing their specialized biologics and therapeutics to market.

/美通社/ - 全球领先的测试、检验和认证公司SGS欣然宣布，已收购位于美国伊利诺伊州芝加哥的专业生物分析测试服务提供商CMIC, INC.。CMIC, INC.成立于2010年，致力于支持北美制药和生物技术制造商将其专业生物制品和治疗产品推向市场。

Its 27,000 square foot GLP-compliant facility delivers bioanalysis across both pre-clinical and clinical phases of the drug development life cycle, accommodating quick turnaround for high-volume projects. This follows the acquisition of another U.S.-based bioanalytical testing service provider last month..

其占地27,000平方英尺、符合GLP规范的设施，提供覆盖药物研发生命周期临床前和临床阶段的生物分析服务，能够满足高通量项目的快速周转需求。此前，该公司于上月收购了另一家美国生物分析测试服务提供商。

'North America is the largest global market for bioanalytical testing services, with demand for advanced, high-precision capabilities continuing to grow,' said Joseph Bower, Head of Life Sciences at SGS in North America. 'With CMIC, INC. joining the SGS laboratory network, we are strengthening our ability to support drug development through high-quality bioanalytical data that demonstrate the safety and efficacy of complex molecule therapies, aligned with regulatory expectations.

“北美是全球生物分析测试服务最大的市场，对先进、高精度能力的需求持续增长。”SGS 北美生命科学部门负责人约瑟夫·鲍尔（Joseph Bower）表示。“随着 CMIC, INC. 加入 SGS 实验室网络，我们正通过提供符合监管预期的高质量生物分析数据，增强支持药物开发的能力，以证明复杂分子疗法的安全性和有效性。”

It is truly exciting to play a critical role behind the advancement of innovative therapies - from biologics to gene therapies - bringing them closer to patients.'.

在推动创新疗法（从生物制品到基因疗法）的发展进程中发挥关键作用，让这些疗法更贴近患者，这确实令人振奋。

Biologics represent a high-growth segment of the pharmaceutical market, alongside continued demand for small molecule and emerging oligonucleotide therapies. At the same time, increased outsourcing across drug development and clinical trials is fueling growth in third-party bioanalytical testing services.

生物制品代表了制药市场中一个高增长的领域，同时小分子药物和新兴的寡核苷酸疗法的需求持续存在。与此同时，药物开发和临床试验中外包服务的增加正在推动第三方生物分析测试服务的增长。

These complex modalities - particularly biologics and oligonucleotides - require highly specialized analytical approaches and are subject to stringent regulatory oversight by agencies such as the U.S. Food and Drug Administration (FDA) and Health Canada. Against this context, the acquisition of CMIC, INC.

这些复杂的药物形式——尤其是生物制剂和寡核苷酸——需要高度专业化的分析方法，并受到美国食品药品监督管理局（FDA）和加拿大卫生部等机构的严格监管。在此背景下，收购CMIC, INC.

works towards achieving SGS's .

致力于实现SGS的目标。

Strategy 27

策略 27

objective to double North American sales between 2023 to 2027 by responding to megatrends driving growth in the TIC industry – including increased regulation and expectations for safety, health and well-being.

目标是通过应对推动检测、检验和认证（TIC）行业增长的宏观趋势——包括日益严格的监管以及对安全、健康和福祉的更高期望——在2023年至2027年间实现北美销售额翻番。

SGS has been supporting the North American pharmaceutical industry for over 30 years across the full drug development life cycle. This regional expertise is complemented by a global network of 20+ laboratories across 11 countries, including 10 GLP-compliant sites, positioning SGS as one of the most comprehensive, wholly owned analytical laboratory networks serving the pharmaceutical and biotechnology sectors worldwide..

三十余年来，SGS 始终为北美制药行业提供覆盖药物研发全生命周期的支持。这一区域专业能力辅以遍布 11 个国家的 20 多家实验室组成的全球网络，其中包括 10 家符合 GLP（良好实验室规范）要求的站点，使 SGS 成为服务于全球制药和生物技术领域的最全面的全资分析实验室网络之一。

CMIC, INC. is a group company of CMIC HOLDINGS Co., Ltd. Following the acquisition, CMIC HOLDINGS Co., Ltd. will continue to collaborate with SGS through CMIC Pharma Science Co., Ltd., its consolidated subsidiary operating analytical laboratories in Japan.

CMIC, INC. 是 CMIC HOLDINGS Co., Ltd. 的集团公司。收购完成后，CMIC HOLDINGS Co., Ltd. 将继续通过其在日本运营分析实验室的合并子公司 CMIC Pharma Science Co., Ltd. 与 SGS 开展合作。

About SGS

关于SGS

SGS is the world's leading Testing, Inspection and Certification company. We operate a network of over 2,500 laboratories and business facilities across 115 countries, supported by a team of over 100,000 dedicated professionals. With more than 145 years of service excellence, we combine the precision and accuracy that define Swiss companies to help organizations achieve the highest standards of quality, compliance and sustainability..

SGS 是全球领先的测试、检验和认证机构。我们在 115 个国家运营着由 2,500 多家实验室和业务设施组成的网络，背后有超过 100,000 名敬业的专业人士提供支持。凭借 145 多年的卓越服务经验，我们将瑞士企业所秉持的精密与准确相结合，助力各类组织实现质量、合规性和可持续性方面的最高标准。

Our brand promise –

我们的品牌承诺——

when you need to be sure

当你需要确保万无一失时

– underscores our commitment to trust, integrity and reliability, enabling businesses to thrive with confidence. We proudly deliver our expert services through the SGS name and a portfolio of trusted specialized brands, including Applied Technical Services, Brightsight, Bluesign and Nutrasource.

– 彰显我们对信任、诚信和可靠性的承诺，使企业能够充满信心地蓬勃发展。我们自豪地通过SGS品牌以及一系列备受信赖的专业品牌组合提供我们的专业服务，其中包括Applied Technical Services、Brightsight、Bluesign和Nutrasource。

SGS is publicly traded on the SIX Swiss Exchange under the ticker symbol SGSN (ISIN CH1256740924, Reuters SGSN.S, Bloomberg SGSN SW).

SGS在瑞士证券交易所（SIX Swiss Exchange）公开上市，股票代码为SGSN（国际证券识别码：CH1256740924，路透社代码：SGSN.S，彭博代码：SGSN SW）。

SOURCE SGS

来源 SGS

21

二十一

%

%

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示